Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Envolizumab in Combination With Sovalteinib for the Treatment of Treated Bile Duct Cancer in an Open, Single-arm, Phase II Clinical Study

NCT05911425 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT05911425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05911425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Envolizumab in Combination With Sovalteinib for the Treatment of Treated Bile Duct Cancer in an Open, Single-arm, Phase II Clinical Study
Lead sponsor
Zhejiang Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2023
Completion date
June 30, 2025
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer